Search

Displaying results 1531 - 1540 of 4207 in total
  1. Drug

    Vepdegestrant

    go.drugbank.com/drugs/DB19006
    ApprovedInvestigational

    Vepdegestrant is a potent, selective, and orally bioavailable PROteolysis TArgeting Chimera (PROTAC) small molecule estrogen receptor (ER) degrader. It was identified through a targeted medicinal chemistry optimization campaign to act as...

  2. Drug

    Amphotericin B

    go.drugbank.com/drugs/DB00681
    ApprovedInvestigational

    Histoplasma capsulatum, Coccidioides immitis, Candida species, Blastomyces dermatitidis, Rhodotorula, Cryptococcus neoformans, Sporothrix schenckii, Mucor mucedo, and Aspergillus fumigatus are all inhibited by

  3. Drug

    Uridine triacetate

    go.drugbank.com/drugs/DB09144
    Approved

    By pre-administering with uridine (as the prodrug uridine triacetate), higher doses of 5-FU can be given allowing for improved efficacy and a reduction in toxic side effects [A18578]. … When intracellular uridine nucleotides are restored into the normal range, overproduction of orotic acid is reduced by feedback inhibition, so that urinary excretion of orotic acid is also reduced.

  4. Drug

    Interferon alfa

    go.drugbank.com/drugs/DB05258
    ApprovedInvestigationalWithdrawn

    Interferon alfa contains several naturally occurring IFN-α subtypes and is purified by affinity chromatography.

  5. Drug

    Abrocitinib

    go.drugbank.com/drugs/DB14973
    ApprovedInvestigational

    Atopic dermatitis is characterized by epidermal hyperplasia, skin barrier dysfunction, and the aberrant activation of immune cells. … [A244549] Abrocitinib was approved by the European Commission on December 10, 2021, for the treatment of moderate-to-severe atopic dermatitis (AD) in adults who are candidates for systemic therapy.

  6. Drug

    Oxybutynin

    go.drugbank.com/drugs/DB01062
    ApprovedInvestigational

    [A183782,L8648] This drug relieves undesirable urinary symptoms, increasing the quality of life for patients affected by OAB. It is often used as first-line therapy for OAB.[A185990]

  7. Drug

    Povidone-iodine

    go.drugbank.com/drugs/DB06812
    ApprovedInvestigational

    This unique complex was discovered in 1955 at the Industrial Toxicology Laboratories in Philadelphia by H. A. Shelanski and M. V. Shelanski.

  8. Drug

    Abarelix

    go.drugbank.com/drugs/DB00106
    ApprovedWithdrawn

    It is marketed by Praecis Pharmaceuticals as Plenaxis. Praecis announced in June 2006 that it was voluntarily withdrawing the drug from the market.

  9. Drug

    Diazepam

    go.drugbank.com/drugs/DB00829
    ApprovedIllicitInvestigationalVet approved

    Its actions are mediated by enhancement of gamma-aminobutyric acid activity.

  10. Drug

    Pramipexole

    go.drugbank.com/drugs/DB00413
    ApprovedInvestigational

    It was first approved by the FDA in 1997 [L5882]. … RLS is a sleep-related disorder characterized by unpleasant sensations in the lower extremities, often accompanied by an uncontrollable urge to move the legs [A176876].